Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Continental Breakfast

Registration Opens

First Look: The Next Wave of Cancer Breakthroughs

Highly creative young investigators describe their most promising commercially
related research. Rapid-fire presentations by two dozen early-career Harvard
Medical School faculty will highlight compelling new discoveries and insights that
will be the cancer care products of the future. These young stars from Brigham and
Women’s Hospital, Massachusetts General Hospital and Dana-Farber Cancer
Institute will each describe their work in highly organized 10-minute sessions. This
session will take place in the Takeda Ballroom. Presenters will be available
immediately following their talk in the third floor GE Foyer.

Discovery Café: Enjoy Lunch with Top Cancer Leadership from across Partners HealthCare

Top Harvard Medical School faculty from Brigham and Women’s Hospital,
Massachusetts General Hospital and Dana-Farber Cancer Institute will host intimate
lunch discussions on developments in their field and their own research. These
internationally renowned leaders will engage on cutting edge research and new
trends in their clinical and research domain. Seating is reserved based on prior
registration. Please check at registration to find if there is open table availability.

A complete list of table hosts and topics is available here: http://worldmedicalinnovation.org/highlights/

Forum Opening

A War or Moonshot: Where Do We Stand?

Forum Co-Chairs Dr. Bertagnolli and Haber provide perspectives on the coming era
of cancer research and care.

Creating a Disruptive Cancer Pipeline

Some companies characterize creating a successful pipeline of disruptive cancer
therapies as an engineering challenge, others describe arranging building blocks or
integrating capabilities from the marketplace – for many it is all of the above.
Considerations include discovering novel targets, novel single agent drugs and
emerging novel mechanisms, new pathways and/or mechanisms of action, new
molecular entities and technology acquisition strategies, among others. The panel,
corporate officers, investors and academic experts pulls back the curtain to discuss
the considerations in pipeline development, the tradeoffs and what it takes to
maintain success over time.

Curative Therapies: The Economics of Game Changing Science

Novel, potentially curative, cancer therapies are coming to market. Recent
experience in Hepatitis C therapy raises the question as to whether a new approach
is needed to design a pricing model that better balances resulting cost pressure
across the delivery system. While most acknowledge systemic cost effectiveness
curative therapies also present many challenges to payers – e.g. a spike in patient
volume and cost as these therapies are introduced. A broad ranging dialogue
has emerged in the cancer community that includes incorporating cost
effectiveness as part of the regulatory approval, shifting incentives for oncologists,
increasing emphasis on early detection, integrating billing codes, bundled
payments and management fees and many others. The panel with top executives
from the pharma, foundation, pharmacy and provider sectors will share insights on
this crucially important topic.

Winning Portfolio Strategy

The many considerations involved in managing a cancer portfolio are among the
most important for company vitality and also play a principal role in determining
the breadth and rate that new therapies reach patients. Considerations include
drug categories (current or potential), use of approved drugs on new tumor
types, product life extension, concentrating on call point strengths vs broadening
into new cancers, technology category strength – e.g. small molecule vs emerging
ones like CAR-T, product lifecycle status, competitive agents, possible portfolio
swaps (e.g. NVS/GSK) and shareholder scrutiny . Panel members from the highest
ranks of the industry — large and emerging companies — will discuss their strategic
approach to balancing considerations they can influence and those that they can’t.

Early Detection and Prevention of Cancer

The prevention of cancer and the development of new strategies to detect cancer
precursors and early-stage malignancies when treatment may be most effective
– clinically and financially — are critical research goals. Our panel of experts reviews
powerful imaging modalities, single-cell analysis of the tumor microenvironment
and next-generation cancer models. Circulating tumor DNA testing to monitor
response to treatment and emergence of cancer resistance—with the objective of
early cancer diagnosis before symptoms appear—will also be detailed.

Innovation Break: Announcing the C³ Prize from Astellas Oncology and the World Medical Innovation Forum

Ropes & Gray Welcome Reception

Ropes & Gray Dinner Program – Fireside Chat: Richard Gonzalez, CEO, AbbVie

Continental Breakfast

Global Cancer Markets

Cancer causes 1 in 7 deaths worldwide. If rates don’t change, the global cancer
burden is expected to increase from 14 million new cases and 8 million cancer
related deaths worldwide to 22 million cases and 13 million deaths by 2030. The
panel will discuss how approaches to deliver innovative technologies differ in
different international markets, what the respective drivers are, as well as
requirements and challenges. Expert panelists from leading international
companies and key governmental entities, including the famed NICE from the UK
NHS, will consider strategies and key trends.

Epigenetics and Novel Cancer Targets

The initiation and progression of cancer is controlled by both genetic and
epigenetic events. Epigenetics, the study of changes that influence how DNA
does its job, is one of the fastest-moving fields in cancer research. Expert corporate
and academic panel members will discuss the promise of epigenetics. They will
describe translating basic epigenetic research into cancer diagnostics and
therapies, emphasizing market opportunities and competitive advantages.

Networking Break

Fireside Chat: Robert Bradway, CEO, Amgen

Immunotherapy I: Checkpoint Activation and Cancer Vaccines

Among the most promising approaches to activating therapeutic antitumor
immunity is the blockade of immune checkpoints. Checkpoint blockade, prevention
of inhibitory signaling that limits activation or function of tumor antigen-specific
T cells responses, is revolutionizing the treatment of many poor-prognosis
malignancies. Expert panelists discuss significant long-term cancer remissions,
potential cures – in some cases – and how boosting the body’s own defenses
is producing stunning results when combined with standard anticancer therapies
and other immunotherapies. They will also detail the experimental accines in
development that are designed to “wake up” the immune system so it will trigger
reliable and effective attacks on cancer cells.

Lunch

Fireside Chat: Andy Slavitt, Acting Administrator, CMS

Fireside Chat: Giovanni Caforio, MD, CEO, Bristol-Myers Squibb

Fireside Chat: Patients Driving Innovation

Immunotherapy II: Cell Based Therapies

Oncology sits on the cusp of a new revolution thanks to the use of human cells as versatile
therapeutic engines. By modifying T cells to express chimeric antigen receptors (CARs) that
recognize cancer-specific antigens, our expert panelists describe how they have been able to prime
cells to recognize and kill tumor cells that would otherwise escape immune detection. They also
detail the various “living drugs” that kill cancer cells and could replace standard oncology
treatments in the future.

Financing Breakthrough Cancer Companies

The global market for oncology therapies is currently more than $100 billion annually, and could
reach $147 billion by the end of the decade. Panel experts discuss the most compelling
technologies, trends driving investment considerations, new models, pricing considerations and
strategies they use as leading oncology investors in both early stage and established companies.

Arms Race in Radiation

The Holy Grail of radiation therapy is to maximize the effectiveness of killing cancer
cells while minimizing the effect on neighboring tissue. Technology meets modern
cancer care with the integration of technologies that offer enormous benefits to
the cancer patient in improved quality of life and increased likelihood of
cure. Expert panelists will highlight current benefits of radiation therapies, the
increasing use of hypofractionated radiation therapy and describe future tools in
development that will have the potential to dramatically improve outcomes.

Breakthrough Devices to Treat Cancer

The increasing demand for early diagnosis of cancer and the growing prevalence of
metastatic brain, lung, breast, prostate and other cancers is driving the oncology
device market. Our experts zero in on innovative technologies that will address
challenges in cancer surgery and pain management.

Study Designs to Meet the Challenges of Personalized Cancer Medicine

Cancer biology indicates that cancer is a large number of niche diseases that may be targeted
with therapies against specific molecular alterations common to multiple tumor types. This
model creates challenges for both drug development and patient care with implications for
initial indication selection and design and execution of clinical trials – from first in human
through post marketing studies. Among the topics the panel will address:
• The availability of biomarkers to stratify trials, select patients and monitor drug response can improve
both trial speed and cost, as well as enable development of companion diagnostics but at the same time
present more complex validation requirements.
• Design of trials using surrogate end points holds great promise but validation of such endpoints is a
regulatory challenge. Adaptive trial designs for dose response, pK/PD and efficacy hold promise but
adoption of such approaches has been slow.
• Cancer immunotherapies create a significant opportunity for development of combination therapies
but the cost of acquiring the approved drug can significantly increase the cost of clinical trials. This may
necessitate new approaches to late preclinical development as well as biomarkers that are early and
accurate indicators of drug response for incorporation in the clinical trial in Phase I/II.
• The cost of current and next generation cancer drugs will require measuring clinical and econometric
outcomes in order to justify reimbursement. This may mandate larger post marketing clinical studies,
including observational trials

Surviving Cancer: New Realities, New Needs

Extraordinary treatment advances have turned many cancers from apparent death sentences
into manageable chronic illnesses with extraordinary consequences for the entire health
care system. In the United States, there are approximately 14 million cancer survivors, up from
just three million four decades ago. Those survivors have unique care requirements, that will
put enormous stress on the system — calling out for new technology solutions. The panel will
discuss requirements technologies and approaches that can help monitor, guide, and connect
patients.

Attendee Reception

Continental Breakfast

Combination Cancer Therapies: Drug Resistance and Therapeutic Index

Study Designs to Meet the Challenges of Personalized Cancer Medicine Game changing modern
cancer therapies—immunotherapies and targeted therapies, among others—do not by themselves
meet the needs of many patients who require alternative strategies to achieve optimal therapeutic
benefit. Panel experts will describe combining these therapies with other drugs, challenges and the
path forward.

Fireside Chat: Joseph Jimenez, CEO, Novartis

Cancer Diagnostics: New Uses, New Reimbursements?

Advances in genetics, genomics and proteomics are driving advances in identifying and treating
disease. Use of genetic testing and molecular diagnostics is rapidly expanding in clinical practice,
creating a new, personalized approach to medicine. Panelists describe key new technologies and
how they will be fully integrated into the delivery of care.

New Philanthropy: Patients Driving Innovation

Philanthropy’s role in driving improved cancer care has evolved rapidly over the
last decade. Disease foundations have become active in nearly every phase of the
care spectrum supporting innovations in the lab, clinic, patient engagement, and
regulatory approval among others. Senior philanthropic leaders will describe how
the foundation community is redefining roles and finding new ways to help
patients as they seek to drive breakthroughs in understanding and care.

Disruptive Dozen

Cancer faculty from the Brigham and Women’s Hospital, Massachusetts General
Hospital, and Dana-Farber Cancer Institute nominated dozens of technologies that
will have the greatest impact on cancer care in the next decade, and then compiled
a ranking of the 12 most disruptive technologies. A panel of experts will announce
and discuss each of the technologies chosen. This intriguing, informative and fun
session will let you in on how the experts view the future in their field.

Boxed Lunches Available

Forum Closing